These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 25907435)
1. [Hepatitis C treatment in special patient groups]. Berenguer M; Jorquera F; Ángel Serra M; Sola R; Castellano G Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():23-36. PubMed ID: 25907435 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384 [TBL] [Abstract][Full Text] [Related]
4. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Rodríguez-Torres M Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341 [TBL] [Abstract][Full Text] [Related]
5. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Fabrizi F; Martin P; Messa P Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277 [TBL] [Abstract][Full Text] [Related]
6. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Verucchi G; Calza L; Manfredi R; Chiodo F Infection; 2004 Feb; 32(1):33-46. PubMed ID: 15007741 [TBL] [Abstract][Full Text] [Related]
8. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Beste LA; Green PK; Ioannou GN Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739 [TBL] [Abstract][Full Text] [Related]
9. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Seden K; Back D Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895 [TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354 [TBL] [Abstract][Full Text] [Related]
12. [Future prospects for hepatitis C treatment: without interferon and ribavirin?]. Lens S; Alfaro I Gastroenterol Hepatol; 2014 May; 37(5):311-21. PubMed ID: 24679376 [TBL] [Abstract][Full Text] [Related]
13. Management of hepatitis C in patients with chronic kidney disease. Carvalho-Filho RJ; Feldner AC; Silva AE; Ferraz ML World J Gastroenterol; 2015 Jan; 21(2):408-22. PubMed ID: 25593456 [TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis C virus infection after liver transplantation. Agarwal K; Barnabas A Dig Liver Dis; 2013 Sep; 45 Suppl 5():S349-54. PubMed ID: 24091115 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594 [TBL] [Abstract][Full Text] [Related]
16. Impact of new treatment options for hepatitis C virus infection in liver transplantation. Righi E; Londero A; Carnelutti A; Baccarani U; Bassetti M World J Gastroenterol; 2015 Oct; 21(38):10760-75. PubMed ID: 26478668 [TBL] [Abstract][Full Text] [Related]
17. Telaprevir: changing the standard of care of chronic hepatitis C. Rajani AK; Ravindra BK; Dkhar SA J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057 [TBL] [Abstract][Full Text] [Related]
18. [Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors]. Ruiz Ramos J; Romero Hernández I; Marrero Álvarez P; Marqués Miñana MR; Fernández Megía MJ; Poveda Andrés JL Gastroenterol Hepatol; 2014 Dec; 37(10):558-63. PubMed ID: 24951300 [TBL] [Abstract][Full Text] [Related]
19. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). ; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L; Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482 [TBL] [Abstract][Full Text] [Related]
20. The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation. Gonzalez SA; Jacobson IM Cleve Clin J Med; 2004 May; 71 Suppl 3():S22-6. PubMed ID: 15468614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]